Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Lifeward Ltd. (LFWD) filed an initial statement of beneficial ownership on Form 3 for Greenwald Yonason, who is identified as a director of the company and not as an officer or 10% owner. The filing reports no transactions or current holdings of Lifeward securities and includes a reference to an Exhibit 24.1 Power of Attorney authorizing the filing.
Lifeward Ltd. (symbol: LFWD) is the issuer of record for a Form 4 filing submitted to the SEC.
Lifeward Ltd. (LFWD) reported that Gabay Avraham has become a reporting person as a director of the company on an initial Form 3. The filing does not list any specific equity holdings or transactions for this reporting person. The remarks section notes an attached Power of Attorney (Exhibit 24.1).
Lifeward Ltd. (LFWD) reported changes to its Board of Directors. On August 14, 2026, the Board appointed Yonason Greenwald and Haggai Zamir as Class III Directors, with initial terms expiring at the 2026 Annual Meeting of Shareholders. Mr. Greenwald will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees, and Mr. Zamir will serve on the Nominating and Corporate Governance Committee.
On August 20, 2026, the Board appointed Avraham Gabay as a Class III Director and Chair of the Board, also with a term expiring at the 2026 Annual Meeting. All three will receive the company’s standard non-employee director compensation. On the same date, Nadav Kidron resigned from the Board, effective immediately; the company states his departure did not result from any disagreement regarding operations, policies, or practices.
Lifeward Ltd. reported second-quarter 2026 revenue of $6.6 million, up modestly from $5.7 million a year earlier, with six-month revenue essentially flat at $10.5 million versus $10.8 million in 2025. Gross profit for the first half was $4.1 million, down from $4.6 million.
The company posted a six‑month net loss of $22.3 million, nearly double the prior-year loss of $11.4 million, driven largely by $7.8 million in net financial expense from warrant and derivative liabilities and interest on new convertible notes. Operating cash outflow was $9.7 million. Management states that recurring losses, negative cash flows and limited liquidity raise substantial doubt about Lifeward’s ability to continue as a going concern without additional financing.
During the period, Lifeward closed the Oratech asset acquisition, allocating $4.9 million to in‑process R&D (expensed immediately) and $6.5 million to acquired cash, and completed the Skelable technology acquisition. It also issued $10 million of senior secured convertible notes with attached warrants and, in a July closing, added $5.6 million more in senior secured convertible notes, while reclassifying certain warrant and derivative liabilities to equity.
Lifeward Ltd. reported second quarter 2026 results showing higher revenue but a larger net loss, alongside significant leadership changes. Revenue increased 16% to $6.6 million from $5.7 million a year earlier, driven by ReWalk Personal exoskeleton sales of $2.5 million and AlterG products and services of $4.1 million. Gross margin was 41%, down from 44% due to higher tariffs, foreign exchange impacts and a 4% revenue-sharing expense tied to the Oramed transaction.
Total operating expenses declined 24% to $6.9 million, reflecting prior-year impairment charges, and operating loss improved 37% to $4.2 million. However, net loss widened to $11.5 million (or $4.12 per share) from $6.6 million, mainly from non-cash fair value charges on warrant and derivative liabilities. On a non-GAAP basis, net loss was $4.1 million. Cash and cash equivalents rose to $9.4 million as of June 30, 2026, versus $2.2 million at year-end 2025, with a pro forma balance of about $11 million including a July 2026 capital raise.
Governance changes include the resignations of directors Robert J. Marshall, Jr., Michael Swinford and William Mark Sigsbee, effective August 13, 2026, with no disagreements cited. Chief Financial Officer Almog Adar will step down effective September 30, 2026, under a separation agreement treated as a termination without cause while he supports the transition.
Lifeward Ltd., an Israeli medical device company focused on exoskeletons and rehabilitation technologies, is registering for resale up to 2,066,662 ordinary shares. These consist of 1,033,331 shares issuable upon conversion of senior secured convertible notes and 1,033,331 shares issuable upon exercise of accompanying warrants from a June 30, 2026 Note and Warrant Financing.
The Initial Notes total $5,580,000 in principal, bear 8% annual interest, mature three years from their original issue date and are convertible at $5.40 per share. The Initial Warrants are immediately exercisable at $5.40 per share for five years. Lifeward is not selling shares in this offering and will receive no proceeds from Selling Shareholder resales, though it may receive cash from any warrant exercises for general corporate purposes. As of July 31, 2026, 2,828,362 ordinary shares were outstanding, and the Nasdaq Capital Market closing price was $7.22 under the symbol “LFWD.” The filing notes a 4.99% Beneficial Ownership Limitation for conversions and exercises and references an audit opinion containing a going concern explanatory paragraph.
Lifeward Ltd., an Israel-incorporated health care biotechnology company limited by shares with principal offices in Hudson, Massachusetts, is conducting an exempt private offering under Regulation D Rule 506(b). The company reports that it has sold $11,160,000 USD of securities.
The offering covers multiple instruments, including equity, debt, options or warrants or other rights to acquire securities, and the underlying securities issuable upon exercise of those rights. This is a new notice, with the first sale occurring on 2026-07-06. The company discloses $0 in finders' fees associated with the offering.
Lifeward Ltd. entered into a new financing arrangement built around senior secured convertible notes and warrants. The company closed an initial issuance of $5,580,000 in notes on July 6, 2026, with a second $5,580,000 tranche available upon meeting performance or share-price conditions.
Each note has a three-year term, carries 8.0% annual interest (rising to 15.0% on default) and is convertible into ordinary shares at an initial price of $5.40 per share. Investors also receive warrants exercisable for up to 100% of the shares underlying each note, also at $5.40 per share, immediately exercisable and expiring after five years. Both notes and warrants include a 4.99% beneficial ownership cap and a 19.99% exchange cap on total share issuance unless shareholders approve more. The securities were sold in a private offering to accredited investors under Rule 506(b) of Regulation D.